Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Squamous Non-small Cell Lung Cancer 1Squamous Non Small Cell Lung Cancer 1Solid Tumors 1Non-small Cell Lung Cancer Metastatic 1Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Gemcitabine 5Paclitaxel 4Nivolumab 3cobimetinib 2atezolizumab 2adavosertib 2Ramucirumab 2N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 2Carboplatin 2zansecimab 1tocilizumab 1tivozanib 1tislelizumab 1temsirolimus 1ridaforolimus 1plocabulin 1pexidartinib 1pevonedistat 1pembrolizumab 1pamiparib 1obinutuzumab 1necitumumab 1liposomal doxorubicin 1lenvatinib 1glasdegib 1futuximab 1demplatin pegraglumer 1birinapant 1avelumab 1Temozolomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Solid Tumors × necitumumab × Clear all
NCT01624467 2016-07-25

A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors

Eli Lilly and Company

Phase 2 Completed
75 enrolled 12 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡